Aprocitentan - Idorsia Pharmaceuticals
Alternative Names: AC 080; ACT-132577; JERAYGO; JNJ-2820; TRYVIOLatest Information Update: 01 Aug 2024
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Amides; Antihypertensives; Cardiovascular therapies; Ethers; Halogenated hydrocarbons; Pyrimidines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypertension
- Phase II Essential hypertension
Most Recent Events
- 25 Jul 2024 Idorsia Pharmaceuticals plans to launch aprocitentan for Hypertension in UK, Canada, and Switzerland
- 01 Jul 2024 Registered for Hypertension (Combination therapy, Treatment-experienced) in European Union (PO)
- 01 Jul 2024 Registered for Hypertension (Combination therapy, Treatment-experienced) in Iceland, Liechtenstein, Norway (PO)